PMID- 23286438
OWN - NLM
STAT- MEDLINE
DCOM- 20131210
LR  - 20190728
IS  - 1873-4286 (Electronic)
IS  - 1381-6128 (Linking)
VI  - 19
IP  - 21
DP  - 2013
TI  - How should we treat hypertension and dyslipidemia in patients with prediabetes?
PG  - 3773-87
AB  - Type 2 diabetes mellitus (T2DM) is a serious health problem with epidemic 
      proportions and associated with high cardiovascular morbidity and mortality. 
      Thus, the prevention or at least delaying the onset of T2DM is imperative. 
      Subjects with impaired glucose metabolism (prediabetes) are highly likely to 
      develop overt T2DM. Treatment of accompanied cardiovascular risk factors, such as 
      hypertension and dyslipidemia, in these patients is frequently complicated as it 
      can impair the already altered glucose homeostasis. This review discusses the 
      pathophysiology of lipid disorders and hypertension in prediabetes along with the 
      effects of lipid modifying and antihypertensive drugs in glucose/insulin 
      metabolism. A critical overview and suggestions of different treatment options 
      for prediabetic patients with dyslipidemia and/or hypertension are also 
      presented.
FAU - Tsimihodimos, Vasilios
AU  - Tsimihodimos V
AD  - Department of Internal Medicine, Medical School, University of Ioannina, 
      Ioannina, Greece. tsimiho@gmail.com
FAU - Florentin, Matilda
AU  - Florentin M
FAU - Elisaf, Moses S
AU  - Elisaf MS
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United Arab Emirates
TA  - Curr Pharm Des
JT  - Current pharmaceutical design
JID - 9602487
RN  - 0 (Antihypertensive Agents)
RN  - 0 (Hypolipidemic Agents)
RN  - 0 (Insulin)
RN  - IY9XDZ35W2 (Glucose)
SB  - IM
MH  - Animals
MH  - Antihypertensive Agents/adverse effects/therapeutic use
MH  - Diabetes Mellitus, Type 2/prevention & control
MH  - Dyslipidemias/*drug therapy/physiopathology
MH  - Glucose/metabolism
MH  - Humans
MH  - Hypertension/*drug therapy/physiopathology
MH  - Hypolipidemic Agents/adverse effects/therapeutic use
MH  - Insulin/metabolism
MH  - Prediabetic State/*complications
MH  - Risk Factors
EDAT- 2013/01/05 06:00
MHDA- 2013/12/16 06:00
CRDT- 2013/01/05 06:00
PHST- 2012/12/16 00:00 [received]
PHST- 2012/12/25 00:00 [accepted]
PHST- 2013/01/05 06:00 [entrez]
PHST- 2013/01/05 06:00 [pubmed]
PHST- 2013/12/16 06:00 [medline]
AID - CPD-EPUB-20121226-20 [pii]
AID - 10.2174/13816128113199990304 [doi]
PST - ppublish
SO  - Curr Pharm Des. 2013;19(21):3773-87. doi: 10.2174/13816128113199990304.